Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain.

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatment -- and that’s set to continue thanks to the ...

The U.S. equity market has been anything but calm in 2025, as several factors, including persistent trade tensions, rising ...

May 5 (Reuters) - Vertex Pharmaceuticals (VRTX.O), opens new tab missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% ...

(Reuters) -Vertex Pharmaceuticals missed Wall Street estimates for quarterly results on Monday due to lower-than-expected sales of its cystic fibrosis (CF) drug Trikafta, sending shares down 2.5% ...

Vertex is already looking beyond the triple therapy concept, towards a Gene Editing mRNA drug, which it says could help the entire global population of CF patients, which is up to 75,000 patients ...

But NICE rejected Vertex’s CF latest drug Orkambi for routine NHS funding in final guidance published in July 2016, saying the drug’s £104,000 per year price tag was too expensive.

Vertex has a strong pain management pipeline, which is likely to help the company emerge as one of the largest players in this market. The CF drug portfolio is the foundation on which Vertex can ...